NIKKEI 225
27,606.46 -79.01 (-0.29%) HANG SENG
21,283.52 -15.18 (-0.07%) CRUDE OIL
78.41 +1.27 (+1.65%) GOLD FUTURES
1,887.90 +3.10 (+0.16%) DOW
33,949.01 -207.68 (-0.61%) BTC-GBP
18,987.96 -354.02 (-1.83%)
Genmab A/S (GNMSF)
| Previous close | 394.30 |
| Open | 391.30 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 389.00 - 392.75 |
| 52-week range | 260.25 - 470.50 |
| Volume | |
| Avg. volume | 832 |
| Market cap | 25.906B |
| Beta (5Y monthly) | 0.66 |
| PE ratio (TTM) | 33.55 |
| EPS (TTM) | 11.71 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 481.51 |
- Globe Newswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; January 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 millio
- Zacks
GILD or GMAB: Which Is the Better Value Stock Right Now?
GILD vs. GMAB: Which Stock Is the Better Value Option?
- Globe Newswire
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company announcement no. 1/2023 regarding transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons it was reported that member of the Board of Directors, Mijke Zachariasse, acquired a total of 175 shares in Genmab A/S due to vesting of restricted stock units (partly as employee of Genmab B.V., partly as board member). The corr
